AI assistant
Sending…
AIM ImmunoTech Inc. — Director's Dealing 2011
Feb 1, 2011
35334_dirs_2011-02-01_a8d1d8f6-8d44-47ff-bae4-44ff47fd07cb.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: HEMISPHERX BIOPHARMA INC (HEB)
CIK: 0000946644
Period of Report: 2010-12-06
Reporting Person: Bernhardt Charles Thomas III (Chief Financial Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2010-12-06 | Options to buy Common Stock | $0.55 | P | 100000 | Acquired | 2020-12-03 | Common Stock (100000) | Direct |
More from AIM ImmunoTech Inc.
Governance Information
2026
Jun 10
Capital/Financing Update
2026
Jun 10
Capital/Financing Update
2026
Jun 8
Report Publication Announcement
2026
Jun 4
Capital/Financing Update
2026
May 21
Capital/Financing Update
2026
May 21
Share Issue/Capital Change
2026
May 19
Capital/Financing Update
2026
May 19
Interim / Quarterly Report
2026
May 15
Regulatory Filings
2026
May 14